AbbVie acquired Cerevel Therapeutics Holdings, Inc. for $8.7 billion, a transaction completed in August 2024, structured as all cash ($45.00 per share).
Cerevel Therapeutics Holdings, Inc. operates in Neuroscience, is based in Cambridge, Massachusetts. Cerevel is a clinical-stage neuroscience biotech with a pipeline spanning schizophrenia, Parkinson's disease and mood disorders, including emraclidine and tavapadon. AbbVie acquired all outstanding shares for $45.00 per share in cash.
AbbVie's existing neuroscience portfolio combined with Cerevel's pipeline represents a significant growth opportunity well into the next decade.
Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade.Richard A. Gonzalez, Chairman and CEO, AbbVie
Advisory firms were not disclosed for this transaction.